Varenicline in the treatment of tobacco dependence
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Varenicline, a partial agonist of alpha(4)beta(2) nicotinic acetylcholine receptors, is the most recently approved drug for smoking cessation. This paper reviews the outcomes of Phase 2 and Phase 3 clinical trials that assess the efficacy of varenicline in comparison to placebo and other smoking cessation pharmacotherapies, ie, sustained-release bupropion (bupropion SR) and nicotine transdermal patch. Varenicline has higher abstinence rates than placebo and the alternative active treatments at the end of standard regimen treatment periods. Significantly higher abstinence rates were also found with varenicline in comparison to both placebo and bupropion SR at the end of a 40-week non-treatment follow-up period. Varenicline typically tripled the abstinence rates compared with placebo. In addition, varenicline reduced craving and withdrawal symptoms as well as some of the positive experiences associated with smoking to a greater extent than placebo, bupropion SR, and nicotine replacement therapy (NRT). These findings are consistent with the proposed agonist/antagonist effects of varenicline. Preliminary studies assessing individual variables such as smoking dependency level and smoking reinforcement types provide justification to examine further the effects of varenicline according to these individual factors. Outcomes from such research could improve our understanding of varenicline's mechanism of action and could ultimately help clinicians to develop individualized smoking cessation programs. Also, given varenicline's ability to reduce the reward from smoking, it might be helpful to use it before cessation to motivate or prepare smokers for a quit attempt.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire
Fagerstrom, K. O., & Schneider, N. G. (1989) · Journal of Behavioral Medicine · doi:10.1007/bf00846549 · Cited by 1,598 · cited 1×
“Nicotine dependence, most often measured by the Fagerström Test for Nicotine Dependence (FTND), is a strong predictor of abstinence, particularly in non-treated smokers (eg, Fagerström and Schneider 1989; Hyland et al 2004; Foulds et al 2006).”
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Development of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302 · cited 1×
“Nicotine dependence is a Substance Use Disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition – Revised (DSM-IV-TR) (APA 2000) and ranks higher on scales of physical and psychological dependency than alcohol, amphetamines, and cannabis (Nutt et al 2007).”
Nicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930 · cited 1×
“Rimonabant reduced nicotine self-administration in rats (Cohen et al 2002) and also decreased the ability of cues to elicit nicotine use in rats (Cohen et al 2005).”
Effects of abstinence from tobacco: Valid symptoms and time course
Hughes, J. (2007) · Nicotine & Tobacco Research · doi:10.1080/14622200701188919 · Cited by 801 · cited 1×
“In addition, withdrawal from nicotine results in a combination of psychological and physical symptoms leading to cravings and a continued desire to smoke (West et al 2006; Hughes 2007).”
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Tonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660 · cited 4×
“A maintenance trial has already established that an extended period of treatment with varenicline does help to maintain abstinence compared with placebo (Tonstad et al 2006).”
InfluentialPharmacology of Nicotine: Addiction and Therapeutics
Benowitz, N. L. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.003121 · Cited by 589
Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533 · cited 10×
“Varenicline was developed to have a high affi nity for α 4 β 2 nAChR in the mesolimbic dopamine system (Coe et al 2005; Rollema et al 2007a) and to act as a selective partial agonist of the α 4 β 2 nAChR.”
InfluentialBupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
Nicotine delivery kinetics and abuse liability.
Henningfield, J. E., & Keenan, R. M. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.61.5.743 · Cited by 411 · cited 1×
“These 2 types of reinforcement are crucial to understanding the complexity of nicotine addiction and how smoking behavior is maintained (Henningfi eld and Keenan 1993).”
Rollema, H., Coe, J. W., Chambers, L. K., Hurst, R. S., Stahl, S. M., & Williams, K. E. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.003 · Cited by 400
Cohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrié, P. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200209000-00018 · Cited by 396 · cited 1×
“Rimonabant reduced nicotine self-administration in rats (Cohen et al 2002) and also decreased the ability of cues to elicit nicotine use in rats (Cohen et al 2005).”
Oncken, C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1571 · Cited by 380
Fenster, C. P., Rains, M. F., Noerager, B., Quick, M. W., & Lester, R. A. J. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-15-05747.1997 · Cited by 332
Balfour, D. (2004) · Nicotine & Tobacco Research · doi:10.1080/14622200412331324965 · Cited by 251 · cited 1×
“The ventral tegmental area contains dopaminergic neurons which release dopamine via mesolimbic projections to the nucleus accumbens (Balfour 2004).”
Cohen, C., Perrault, G., Griebel, G., & Soubrié, P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300541 · Cited by 251
Marubio, L. M., Gardier, A. M., Durier, S., David, D., Klink, R., Arroyo‐Jimenez, M. M., McIntosh, J. M., Rossi, F., Champtiaux, N., Zoli, M., et al. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02564.x · Cited by 242
Pidoplichko, V. I., Noguchi, J., Areola, O. O., Liang, Y., Peterson, J., Zhang, T., & Dani, J. A. (2004) · Learning & Memory · doi:10.1101/lm.70004 · Cited by 196 · cited 1×
“Consequently, these receptors are thought to play a mediating role in dopamine release following the intake of nicotine, which is in turn linked to nicotine’s reinforcing effects (Kelley 2002; Pidoplichko et al 2004; Foulds 2006).”
A double-blind study evaluating the long-term safety of varenicline for smoking cessation
Williams, K. E., Reeves, K. R., Billing, C. B., Pennington, A. M., & Gong, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182185 · Cited by 184
Foulds, J. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00955.x · Cited by 136 · cited 4×
“Consistent with the proposed agonist effects of varenicline (Coe et al 2005; Foulds 2006; Rollema et al 2007a), varenicline participants reported signifi cantly lower urge to smoke (p (cid:1) 0.001), negative affect (p (cid:1) 0.001), and restlessness (p (cid:1) 0.05) on the subscales of the MNWS…”
InfluentialVarenicline Versus Bupropion SR or Placebo for Smoking Cessation: A Pooled Analysis
Nides, M. (2008) · American Journal of Health Behavior · doi:10.5993/ajhb.32.6.10 · Cited by 121
Cited by
Smoking and suicide: A brief overview
Hughes, J. R. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.06.003 · Cited by 236
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub4 · Cited by 46
Plasticity of Addiction: A Mesolimbic Dopamine Short‐Circuit?
Niehaus, J. L., Cruz‐Bermúdez, N. D., & Kauer, J. A. (2009) · The American Journal on Addictions · doi:10.1080/10550490902925946 · Cited by 42
The effects of varenicline on stress-induced and cue-induced craving for cigarettes
Ray, L. A., Lunny, K., Bujarski, S., Moallem, N., Krull, J. L., & Miotto, K. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.015 · Cited by 27
Metadata
- Authors
- Fagerstrom, K.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2008-04
- Volume
- 4
- Issue
- 2
- Pages
- 353
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W2006148198
- Cited by
- 76
- References
- 25
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.